Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405813 | 0.98 | PAOX (0.53) | PAOXSIGMAR1USP2ALDH1A1HPGD | |
| SCHEMBL5405613 | 0.98 | PAOX (0.53) | PAOXSIGMAR1USP2ALDH1A1HPGD | |
| SCHEMBL4420470 | 0.98 | PAOX (0.53) | PAOXSIGMAR1USP2ALDH1A1HPGD | |
| SCHEMBL5385764 | 0.98 | PAOX (0.53) | PAOXSIGMAR1USP2ALDH1A1HPGD | |
| SCHEMBL1099746 | 0.92 | PAOX (0.47) | PAOXSIGMAR1USP2ALDH1A1HPGD | |
| SCHEMBL508711 | 0.87 | HRH3 (0.52) | PAOXHRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL508910 | 0.87 | — | — | |
| SCHEMBL6663287 | 0.87 | PAOX (0.60) | PAOXSIGMAR1USP2ALDH1A1HPGD | |
| SCHEMBL20234244 | 0.87 | PAOX (0.60) | PAOXSIGMAR1USP2ALDH1A1HPGD | |
| SCHEMBL31632710 | 0.84 | PAOX (0.64) | PAOXSIGMAR1USP2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461375-B2 | Method for the continuous production of alkyl(meth)acrylates with multiple catalyst recycling | EVONIK RÖHM GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| EP-1583733-B1 | IMPROVED METHOD FOR THE CONTINUOUS PRODUCTION OF ALKYL(METH)ACRYLATES WITH MULTIPLE CATALYST RECYCLING | EVONIK ROEHM GMBH (DE) | 2013-04-24 | — | — | EP | disclosed |
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | disclosed |
| CN-101821279-A | Certain chemical entities, compositions, and methods | CYTOKINETICS INC | 2010-09-01 | — | — | CN | disclosed |
| US-7268251-B2 | Method for producing (meth) acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-11 | — | — | US | disclosed |
| US-20060211880-A1 | Method for the continuous production of alkyl(meth)acrylates with multiple catalyst recycling | ROEHM GMBH & CO. KG (DE) | 2006-09-21 | — | — | US | disclosed |
| US-7026503-B2 | Method for producing (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | disclosed |
| EP-1399408-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| EP-1583733-A1 | IMPROVED METHOD FOR THE CONTINUOUS PRODUCTION OF ALKYL(METH)ACRYLATES WITH MULTIPLE CATALYST RECYCLING | Röhm GmbH & Co. KG (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-20040171868-A1 | Method for producing (meth) acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | US | disclosed |
| US-20040158096-A1 | Method for producing (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-12 | — | — | US | disclosed |
| WO-2004063140-A1 | IMPROVED METHOD FOR THE CONTINUOUS PRODUCTION OF ALKYL(METH)ACRYLATES WITH MULTIPLE CATALYST RECYCLING | Röhm GmbH & Co. KG (DE) | 2004-07-29 | — | — | WO | disclosed |
| EP-1399408-A1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1399409-A1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002100815-A1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100814-A1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | WO | disclosed |
| EP-0215435-B1 | 2-OXA-ISOCEPHEM COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-4831026-A | ANTIBIOTICS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | disclosed |
| EP-0215435-A1 | 2-Oxa-isocephem compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171868-A1 | Method for producing (meth) acrylic acid esters | ADH1A, ADH5, ADH1C | PAOX 1256/4885SIGMAR1 2292/4885USP2 839/4885 |
| US-20060211880-A1 | Method for the continuous production of alkyl(meth)acrylates with multiple catalyst recycling | ADH5, ADH1A, ADH1C | PAOX 317/4885SIGMAR1 1672/4885USP2 987/4885 |
| US-20040158096-A1 | Method for producing (meth)acrylic acid esters | ADH1A, ADH5, ADH1C | PAOX 620/4885SIGMAR1 975/4885USP2 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.